{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:46:08Z","timestamp":1793277968030,"version":"4.5.0"},"reference-count":89,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:sec id=\"ab-jrv250036-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Head and neck cancer, which arises in the lining or mucosa of the upper aerodigestive tract, specifically the oral cavity, oropharynx, larynx, hypopharynx, and paranasal sinuses, is the seventh most common cancer worldwide. In 2024, approximately 71\u202f110 individuals in the US were diagnosed with head and neck cancer, and it accounted for 16\u202f110 deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250036-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Approximately 90% of head and neck cancers are squamous cell carcinomas. Worldwide, tobacco and alcohol use are the most prevalent risk factors. In the US and Europe, 60% to 70% of newly diagnosed oropharynx cancers (a subset of head and neck cancers) are caused by human papillomavirus (HPV) infection. At presentation, approximately 30% of patients with head and neck cancer have early-stage or localized disease (tumor &amp;amp;lt;4 cm without regional lymph nodes involvement), 60% have locoregionally advanced disease (tumor \u22654 cm with local invasion and\/or regional lymphadenopathy) and 10% have metastatic disease. Up to 10% of oropharynx squamous cell carcinomas present as squamous cell carcinomas of unknown primary. Standard treatment for localized head and neck cancer is surgery or radiotherapy, which are each associated with a 5-year overall survival rate of 70% to 90%. For locoregionally advanced head and neck cancer, multimodality treatment includes surgery followed by postoperative radiation with or without chemotherapy or concomitant chemotherapy (with cisplatin as the preferred agent), and radiation with surgery is reserved for persistent or recurrent disease. With these treatments for locoregionally advanced head and neck cancer, 5-year overall survival rates are 25% to 60% and more than 80% for HPV-associated oropharynx cancer. Choice of treatment for locoregionally advanced head and neck cancer should involve shared decision-making and consideration of effects on speech and swallow function and appearance. First-line treatment for patients with incurable locoregional recurrences or distant metastatic disease is immunotherapy with programmed death ligand-1 inhibition (ie, pembrolizumab) alone or in combination with platinum-doublet chemotherapy. With treatment, patients with incurable locoregional recurrences or distant metastatic disease have a median survival of 12 to 15 months, and 5-year survival rates are less than 20%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250036-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Head and neck cancer is the seventh most common cancer worldwide. In the US and Europe, 60% to 70% of incident oropharynx cancers are associated with HPV infection. Standard treatment for localized head and neck cancer is surgery or radiotherapy. Locoregionally advanced disease is treated with surgery followed by radiation with or without chemotherapy or concurrent chemoradiation. First-line treatment for advanced disease is immunotherapy alone or with chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.21733","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:30:38Z","timestamp":1765816238000},"page":"531","source":"Crossref","is-referenced-by-count":101,"title":["Head and Neck Cancer"],"prefix":"10.1001","volume":"335","author":[{"given":"Lara A.","family":"Dunn","sequence":"first","affiliation":[{"name":"Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[{"name":"Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Pfister","sequence":"additional","affiliation":[{"name":"Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"jrv250036r1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer.","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"issue":"10318","key":"jrv250036r2","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer.","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"jrv250036r3","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"jrv250036r4","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1002\/lary.25465","article-title":"Sinonasal malignancies: a population-based analysis of site-specific incidence and survival.","volume":"125","author":"Dutta","year":"2015","journal-title":"Laryngoscope"},{"issue":"5","key":"jrv250036r5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/aje\/kwt029","article-title":"Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.","volume":"178","author":"Wyss","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"32","key":"jrv250036r6","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States.","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv250036r7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.6004\/jnccn.2017.0101","article-title":"NCCN Guidelines Insights: Head and Neck Cancers, version 2.2017.","volume":"15","author":"Adelstein","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"jrv250036r8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN Guidelines Insights: Head and Neck Cancers, version 1.2022.","volume":"20","author":"Caudell","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"jrv250036r9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/PAP.0b013e3181f895c1","article-title":"Human papillomavirus detection in head and neck squamous cell carcinomas.","volume":"17","author":"Snow","year":"2010","journal-title":"Adv Anat Pathol"},{"issue":"14","key":"jrv250036r10","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/cncr.31385","article-title":"Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults.","volume":"124","author":"Windon","year":"2018","journal-title":"Cancer"},{"key":"jrv250036r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104551","article-title":"Global patterns and trends in cancers of the lip, tongue and mouth.","volume":"102","author":"Miranda-Filho","year":"2020","journal-title":"Oral Oncol"},{"issue":"7","key":"jrv250036r12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and neck cancers, version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"jrv250036r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102143","article-title":"Risk factors associated with head and neck cancer in former smokers: a Brazilian multicentric study.","volume":"78","author":"Gislon","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"jrv250036r14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S1470-2045(08)70173-6","article-title":"Smokeless tobacco and cancer.","volume":"9","author":"Boffetta","year":"2008","journal-title":"Lancet Oncol"},{"issue":"10","key":"jrv250036r15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jnci\/djk179","article-title":"Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.","volume":"99","author":"Hashibe","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"jrv250036r16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ije\/dyp291","article-title":"Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk.","volume":"39","author":"Marron","year":"2010","journal-title":"Int J Epidemiol"},{"issue":"4","key":"jrv250036r17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.coms.2018.06.001","article-title":"Epidemiology and demographics of the head and neck cancer population.","volume":"30","author":"Cohen","year":"2018","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"1","key":"jrv250036r18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<128::AID-IJC20>3.0.CO;2-M","article-title":"Paan without tobacco: an independent risk factor for oral cancer.","volume":"86","author":"Merchant","year":"2000","journal-title":"Int J Cancer"},{"issue":"6","key":"jrv250036r19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/1097-0142(19950315)75:6<1343::AID-CNCR2820750617>3.0.CO;2-T","article-title":"Second primary tumors in patients with head and neck squamous cell carcinoma.","volume":"75","author":"Jones","year":"1995","journal-title":"Cancer"},{"issue":"4","key":"jrv250036r20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood-2002-07-2170","article-title":"A 20-year perspective on the International Fanconi Anemia Registry (IFAR).","volume":"101","author":"Kutler","year":"2003","journal-title":"Blood"},{"key":"jrv250036r21","doi-asserted-by":"crossref","first-page":"S619","DOI":"10.1016\/j.annonc.2024.08.921","article-title":"859P Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).","volume":"35","author":"Dunn","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"jrv250036r22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1470-2045(14)70471-1","article-title":"HPV DNA, E6\/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis.","volume":"15","author":"Ndiaye","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"jrv250036r23","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.2014.55.1341","article-title":"Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.","volume":"32","author":"D\u2019Souza","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv250036r24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"29","key":"jrv250036r25","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma.","volume":"33","author":"Gillison","year":"2015","journal-title":"J Clin Oncol"},{"key":"jrv250036r26","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9051854","article-title":"Chemoprevention of head and neck cancers: does it have only one face?","volume":"2018","author":"Siemianowicz","year":"2018","journal-title":"Biomed Res Int"},{"issue":"6","key":"jrv250036r27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.oraloncology.2010.02.016","article-title":"Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management.","volume":"46","author":"van der Waal","year":"2010","journal-title":"Oral Oncol"},{"issue":"3","key":"jrv250036r28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jop.12339","article-title":"Malignant transformation of oral leukoplakia: a systematic review of observational studies.","volume":"45","author":"Warnakulasuriya","year":"2016","journal-title":"J Oral Pathol Med"},{"issue":"6","key":"jrv250036r29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.oraloncology.2004.12.003","article-title":"Oral erythroplakia: a review.","volume":"41","author":"Reichart","year":"2005","journal-title":"Oral Oncol"},{"issue":"5","key":"jrv250036r30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaoto.2014.141","article-title":"Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer.","volume":"140","author":"McIlwain","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"jrv250036r31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/v13071297","article-title":"Human papillomavirus and squamous cell carcinoma of unknown primary in the head and neck region: a comprehensive review on clinical implications.","volume":"13","author":"Larsen","year":"2021","journal-title":"Viruses"},{"issue":"12","key":"jrv250036r32","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1002\/lary.20638","article-title":"Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site.","volume":"119","author":"Cianchetti","year":"2009","journal-title":"Laryngoscope"},{"issue":"4","key":"jrv250036r33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4065\/83.4.489","article-title":"Head and neck cancer: changing epidemiology, diagnosis, and treatment.","volume":"83","author":"Marur","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"jrv250036r34","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hed.20849","article-title":"Fine-needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis.","volume":"30","author":"Tandon","year":"2008","journal-title":"Head Neck"},{"issue":"1","key":"jrv250036r35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma.","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"jrv250036r36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","article-title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis.","volume":"24","author":"Mehanna","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"jrv250036r37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oraloncology.2015.01.004","article-title":"(18)FDG-PET\/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis.","volume":"51","author":"Sun","year":"2015","journal-title":"Oral Oncol"},{"issue":"2","key":"jrv250036r38","first-page":"122","article-title":"Head and neck cancers: major changes in the American Joint Committee on cancer eighth edition cancer staging manual.","volume":"67","author":"Lydiatt","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"jrv250036r39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11912-019-0799-x","article-title":"Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications.","volume":"21","author":"Zanoni","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"jrv250036r40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoto.2015.2480","article-title":"Incidence of suicide in patients with head and neck cancer.","volume":"141","author":"Kam","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"jrv250036r41","article-title":"Epidemiological trends of head and neck cancer: a population-based study.","volume":"2021","author":"Guo","year":"2021","journal-title":"Biomed Res Int"},{"issue":"30","key":"jrv250036r42","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.2014.55.1937","article-title":"Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.","volume":"32","author":"Fakhry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv250036r43","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/s41416-022-01945-w","article-title":"Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis.","volume":"127","author":"Caini","year":"2022","journal-title":"Br J Cancer"},{"issue":"16_suppl","key":"jrv250036r44","article-title":"Osteoradionecrosis in head and neck cancer patients: risk factors and comparison of grading systems.","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv250036r45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0194599813512783","article-title":"Survival differences between organ preservation surgery and definitive radiotherapy in early supraglottic squamous cell carcinoma.","volume":"150","author":"Arshad","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"jrv250036r46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"jrv250036r47","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/lary.23294","article-title":"Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins.","volume":"122","author":"Weinstein","year":"2012","journal-title":"Laryngoscope"},{"issue":"6","key":"jrv250036r48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJMoa1506007","article-title":"Elective versus therapeutic neck dissection in node-negative oral cancer.","volume":"373","author":"D\u2019Cruz","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250036r49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.otc.2005.11.005","article-title":"The surgical management of oral cancer.","volume":"39","author":"Campana","year":"2006","journal-title":"Otolaryngol Clin North Am"},{"issue":"1","key":"jrv250036r50","first-page":"31","article-title":"An update on larynx cancer.","volume":"67","author":"Steuer","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"jrv250036r51","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2015.03.004","article-title":"Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes.","volume":"92","author":"Grover","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"jrv250036r52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv250036r53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv250036r54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"jrv250036r55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"jrv250036r56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2004.08.021","article-title":"Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.","volume":"22","author":"Denis","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"jrv250036r57","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","article-title":"PET-CT surveillance versus neck dissection in advanced head and neck cancer.","volume":"374","author":"Mehanna","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv250036r58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"10166","key":"jrv250036r59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"issue":"10166","key":"jrv250036r60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"jrv250036r61","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 1201)\u2014a Trans-Tasman Radiation Oncology Group study.","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"jrv250036r62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer.","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"jrv250036r63","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"issue":"5","key":"jrv250036r64","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","article-title":"Long-term follow-up of the RTOG 9501\/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.","volume":"84","author":"Cooper","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"jrv250036r65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"jrv250036r66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"issue":"25","key":"jrv250036r67","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.","volume":"32","author":"Cohen","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"jrv250036r68","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250036r69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","article-title":"Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.","volume":"12","author":"Lorch","year":"2011","journal-title":"Lancet Oncol"},{"issue":"17","key":"jrv250036r70","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv250036r71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer.","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"issue":"10212","key":"jrv250036r72","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"jrv250036r73","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer.","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250036r74","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","article-title":"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"key":"jrv250036r75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"issue":"10167","key":"jrv250036r76","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"jrv250036r77","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-009-0999-4","article-title":"Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck.","volume":"65","author":"Cho","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"jrv250036r78","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv250036r79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"16","key":"jrv250036r80","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.3390\/cancers14163894","article-title":"Oligometastatic head and neck cancer: challenges and perspectives.","volume":"14","author":"Bahig","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"jrv250036r81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0360-3016(99)00558-1","article-title":"Toxicity in head and neck cancer: a review of trends and issues.","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"jrv250036r82","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110329","article-title":"Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: results of the CisFRad (GORTEC 2015-02) randomized phase II trial.","volume":"197","author":"Borel","year":"2024","journal-title":"Radiother Oncol"},{"issue":"4","key":"jrv250036r83","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.prro.2024.02.008","article-title":"Osteoradionecrosis rates after head and neck radiation therapy: beyond the numbers.","volume":"14","author":"Yang","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"jrv250036r84","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1056\/NEJM199308053290603","article-title":"Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer.","volume":"329","author":"Johnson","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250036r85","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ijrobp.2007.01.019","article-title":"Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer.","volume":"68","author":"Chambers","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"jrv250036r86","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2012.03.053","article-title":"Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review.","volume":"84","author":"Koyfman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"jrv250036r87","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2022.17064","article-title":"Recommendations for care of survivors of head and neck cancer.","volume":"328","author":"Auger","year":"2022","journal-title":"JAMA"},{"issue":"20","key":"jrv250036r88","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1002\/cncr.31675","article-title":"Suicide risk among cancer survivors: Head and neck versus other cancers.","volume":"124","author":"Osazuwa-Peters","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"jrv250036r89","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.27892","article-title":"Impact of positron emission tomography\/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence.","volume":"119","author":"Ho","year":"2013","journal-title":"Cancer"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2842834\/jama_dunn_2025_rv_250036_1770050834.14866.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:00:40Z","timestamp":1770739240000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2842834"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.21733","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}